Tokyo – (business wire)– Aculys Pharma, Inc. (“Aculys”), a company focused on the development and commercialization of innovative new medicines in the fields of neurology and psychiatry, and Four H, Inc. (“Four H”) – a home-based company specializing in wellness technology uses wearable devices to assist patients with excessive daytime sleepiness (EDS) associated with narcolepsy and obstructive sleep apnea syndrome (OSAS) We announced an exploratory research collaboration.
Acuris is promoting DX (digital transformation) in clinical trials and medical care with the aim of establishing a new drug model. In this exploratory research collaboration, initiated in conjunction with 4H, Aculys will collect not only sleep, activity, and heart rate data from wearable devices worn each night during the clinical trial, but also subjective sleep data from trial participants. We also collect ratings. These data will be analyzed in conjunction with other data from clinical trials with the goal of identifying sleep-related digital biomarkers.
This exploratory research program is characterized by the following three points.
-
Objective understanding of narcolepsy, OSAS and its characteristics (sleep state, daytime sleepiness, etc.)
-
Analysis of patient subjective evaluation and objective evaluation by wearable device using AI etc.
-
Development of appropriate and highly reliable digital biomarkers for future clinical trials and clinical sites
Through this approach, which is unprecedented in conventional clinical trials of sleep-related diseases, we are able to objectively understand the patient’s sleep state, analyze daytime sleepiness patterns, extract sleep characteristics, and compare daytime activities with patients. Results such as data are expected. Detection of asymptomatic people and the onset of daytime sleepiness.
Sleep disorders are difficult to identify objectively and rely heavily on the patient’s own memory and self-report, creating challenges in diagnosis and appropriate treatment.
This exploratory research will enable us to more accurately understand the sleep and lifestyle habits of individual patients, which has been difficult to measure in the past. In the long term, we jointly plan to build a comprehensive sleep ecosystem for our patients. Personalized data to improve patient quality of life and productivity. A quality disease management program that patients can use at home.
Sleep Disorders* in Japan
The impact of sleep disorders on Japanese society is immeasurable.Presenteeism (reduced work productivity due to health problems) and absenteeism (absence from work or sick leave due to health problems) cost Japan about 3% of its GDP, or about 15 trillion yen, in economic losses. Studies show that it causes1Also, because the importance of sleep is not understood, Japanese sleep less than other countries. The Japanese government’s “National Health Promotion Campaign for the 21st Century (Health Japan 21)” includes sleep as one of the important themes in raising awareness.2-3.
Sleep disturbances are also factors that prevent proper sleep and daytime sleepiness. Delays in appropriate medical intervention for sleep disorders and their associated complications (cardiovascular disease, depression, etc.) have been reported to increase costs for society as a whole, including medical expenses.4-7In order to improve patients’ quality of life, prognosis, productivity, etc., it is necessary to accurately detect sleep disorders and provide appropriate medical care at an early stage.
* A general term for sleep-related disorders such as insomnia, sleep-related breathing disorders (OSAS, etc.), and central hypersomnia (narcolepsy, etc.)
About 4H Co., Ltd.
Health infrastructure is indispensable for people to maintain a healthy life and to be able to pursue happiness and lead active lives. Our mission is to foster a health industry that supports health. By building an infrastructure for people to maintain their health and collaborating with medical institutions, pharmaceutical companies, medical device manufacturers, and health-related companies, we aim to realize a society where minors can maintain their health. disease.
Company name: Four H Co., Ltd.
Address: LINK SQUARE SHINJUKU 16F, 5-27-5 Sendagaya, Shibuya-ku, Tokyo
Representative Director: Jun Koshio
Established: June 2020
URL: https://www.four-h.co.jp
About Acrys Pharma
Aculys Pharma is a clinical-stage biopharmaceutical company focused on commercializing neurological innovations for patients in Japan. Aculys was founded in 2021 to facilitate access to neurological innovation. We are working to shorten the drug lag in Japan by developing and commercializing new central nervous system drugs. Reduce time to market by applying blockchain and AI technology. We provide services that improve healthcare for patients, their families, healthcare professionals, and society.
Company name: Acrys Pharma Co., Ltd.
Address: The Argyle Aoyama, 2-14-4 Kita-Aoyama, Minato-ku, Tokyo
Representative: Issei Tsunaba
Established: January 2021
URL: https://aculys.com
References:
-
Hafner M et al. Why Sleep Matters – The Economic Cost of Inadequate Sleep.Cambridge, UK: RAND Europe; 2016
-
OECD (2009), Society at a Glance 2009: OECD Social Indicators, OECD Publishing, Paris.
-
Ministry of Health, Labor and Welfare 2019 National Health and Nutrition Survey Report
-
Lyons MM et al. The global burden of sleep-disordered breathing and its impact. Respirology Jul 2020;25(7):690-702.
-
Scale TL, scalar DA. Economic impact of sleep disorders. Pharmacoeconomics 2010;28(11):1015–23.
-
Léger D, Bayon V, Larvan JP, et al. The economic impact of sleep apnea. Sleep Medicine Revised 2012;16: 455–62.
-
Flores NM, Villa KF, Black J, Chervin RD, Witt EA. The human and economic burden of narcolepsy. J Clean Sleep
The information regarding pharmaceuticals contained in this release is for the purpose of disclosing our management information and is not intended to advertise or advertise such pharmaceuticals.
